Sao Paulo, June 2021 – Eurofarma, with presence in 20 Countries of Latin America and one of the pharmaceuticals that invests most in research and development in the region, brings with exclusivity for the commercialization EXPAREL®, injectable suspension of liposomal bupivacaine, medicine indicated for the control of postoperative pain. The partnership was signed with Pacira BioSciences, Inc. (Nasdaq: PCRX), which is industry leader in its commitment to non-opioid pain management and regenerative health solutions.

EXPAREL® brings the concept of extended action release of the active ingredient bupivacaine through the critical first few days after surgery, allowing doctors to discharge their patients with more peace of mind after surgery and with fewer opioids.

“This new partnership reflects the tireless work to expand our operations in the region, where we are already a relevant player and where we have achieved more and more space in recent years. For 2022, our goal is to have 30% of all revenues coming from international operations and we are certain that, along with Pacira, we will, over the next few years, expand even more our representation in Latin America with an innovative product”, says Martha Penna, Vice President of Innovation at Eurofarma.

“Through this distribution agreement with Eurofarma, Pacira is significantly expanding its global footprint in one of the fastest growing international markets. This partnership is a key achievement in our global expansion strategy and supports our mission to bring EXPAREL® to patients around the world who are in need of a safe and effective opioid alternative for managing postsurgical pain and reducing length of stay,” said Max Reinhardt, President ROW for Pacira BioSciences. “The Eurofarma team has considerable experience introducing and marketing innovative medical products throughout Latin America and we are confident they will be an ideal partner in this region.”

Indication and Efficacy of EXPAREL®

Commercialized in the US since 2012 and used in a successful manner in more than 8 million patients, EXPAREL® is indicated for a diversity of medical specialties like Orthopedics, Plastic Surgery, Bariatric Surgery, General Surgery, Pediatric Surgery and Anesthesiology, enabling its application in surgeries for postoperative pain control through infiltration or interscalene brachial plexus nerve block.

Pacira has conducted robust clinical development, having performed 40 clinical trials of Phases I to III besides 24 Studies of Phase IV. These studies have shown a reduction of up to 78% in the use of opioids after surgery and better pain control. 

Commercialization and Distribution

Under the terms of the Agreement, Eurofarma will have exclusive right to commercialize and distribute EXPAREL® in Latin America, including Argentina, Brazil, Colombia, Mexico, among others. In addition, Eurofarma will be responsible for executing regulatory registers of EXPAREL® in these Countries. Pacira will receive royalties based on the future sale of the product by Eurofarma, in addition to receiving milestone payments that are triggered by the execution of certain regulatory and commercial events.

Considering all regulatory validations for the start of sales of the product, the expectation is that it will be available to the local market up to 2025. 

About Eurofarma Group

As the first multinational pharmaceutical enterprise with 100% Brazilian capital, the Eurofarma Group has been operating in the pharmaceutical industry since its establishment in 1972, producing and marketing innovative healthcare products and services to improve people’s quality of life. A very diversified company, Eurofarma operates in all major segments, such as Prescription, Non-Prescription, Generic, Hospital, Oncology, and Veterinary Drugs. In Brazil alone, it offers more than 430 products in over 1,000 SKUs, serves all medical specialties, and covers upwards of 200 therapeutic classes, accounting for 80% of the total market.

The Eurofarma Group has own operations in 20 countries, with an industrial park in Brazil and plants in six more Latin American countries. Reported net sales totaled BRL 5.7 billion in 2020 and the Group employs over 7,600 people.

Para saber mais, acesse www.eurofarma.com.

About Pacira BioSciences

Pacira BioSciences, Inc. (Nasdaq: PCRX) is the industry leader in its commitment to non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. The company’s long-acting local analgesic, EXPAREL® (bupivacaine liposome injectable suspension) was commercially launched in the United States in April 2012. EXPAREL® utilizes DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. In April 2019, Pacira acquired the iovera° system, a handheld cryoanalgesia device used to deliver precise, controlled doses of cold temperature only to targeted nerves. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit www.pacira.com.